Response by regimen category
| . | Patients ever achieved a response∗ . | Patients with evaluable regimen, n . | |
|---|---|---|---|
| Yes, n (%) . | No, n (%) . | ||
| Anti-IL6 w/wo corticosteroids† | 29 (50.0) | 29 (50.0) | 58 |
| Siltuximab w/wo corticosteroids | 22 (52.4) | 20 (47.6) | 42 |
| Tocilizumab w/wo corticosteroids | 8 (44.4) | 10 (55.6) | 18 |
| Rituximab w/wo corticosteroids | 7 (26.9) | 19 (73.1) | 26 |
| Chemotherapy-based regimen | 13 (52.0) | 12 (48.0) | 25 |
| Immunomodulator w/wo corticosteroids | 4 (19.0) | 17 (81.0) | 21 |
| Anti-IL6 + rituximab w/wo other | 5 (41.7) | 7 (58.3) | 12 |
| Anti-IL6 + immunomodulator(s) w/wo corticosteroids | 6 (60.0) | 4 (40.0) | 10 |
| Anti-IL6 + procedure w/wo corticosteroids | 0 | 1 (100) | 1 |
| Rituximab + immunomodulator(s) w/wo corticosteroids | 1 (12.5) | 7 (87.5) | 8 |
| Corticosteroids | 1 (2.8) | 35 (97.2) | 36 |
| Procedure + drug therapy | 1 (25.0) | 3 (75.0) | 4 |
| Procedure | 0 | 2 (100) | 2 |
| No medical treatment | 0 | 2 (100) | 2 |
| . | Patients ever achieved a response∗ . | Patients with evaluable regimen, n . | |
|---|---|---|---|
| Yes, n (%) . | No, n (%) . | ||
| Anti-IL6 w/wo corticosteroids† | 29 (50.0) | 29 (50.0) | 58 |
| Siltuximab w/wo corticosteroids | 22 (52.4) | 20 (47.6) | 42 |
| Tocilizumab w/wo corticosteroids | 8 (44.4) | 10 (55.6) | 18 |
| Rituximab w/wo corticosteroids | 7 (26.9) | 19 (73.1) | 26 |
| Chemotherapy-based regimen | 13 (52.0) | 12 (48.0) | 25 |
| Immunomodulator w/wo corticosteroids | 4 (19.0) | 17 (81.0) | 21 |
| Anti-IL6 + rituximab w/wo other | 5 (41.7) | 7 (58.3) | 12 |
| Anti-IL6 + immunomodulator(s) w/wo corticosteroids | 6 (60.0) | 4 (40.0) | 10 |
| Anti-IL6 + procedure w/wo corticosteroids | 0 | 1 (100) | 1 |
| Rituximab + immunomodulator(s) w/wo corticosteroids | 1 (12.5) | 7 (87.5) | 8 |
| Corticosteroids | 1 (2.8) | 35 (97.2) | 36 |
| Procedure + drug therapy | 1 (25.0) | 3 (75.0) | 4 |
| Procedure | 0 | 2 (100) | 2 |
| No medical treatment | 0 | 2 (100) | 2 |
Patients with >1 instance of the same regimen category are considered to have achieved response if response was achieved at least 1 time.
Includes patients ever treated with either siltuximab w/wo corticosteroids and/or tocilizumab w/wo corticosteroids. Best response among those regimens is included; therefore, the number of patients who are evaluable for each siltuximab w/wo corticosteroids and tocilizumab w/wo corticosteroids may not sum to the number of patients who are evaluable for anti-IL6 w/wo corticosteroids